Want to see JP:4563 full AI Analyst Report?

AnGes (4563) Price & Analysis

1 Followers

4563 Stock Chart & Stats

¥47.00

¥0.00(0.00%)

At close: Jul 27 4:00 PM EDT

¥47.00

¥0.00(0.00%)

Day’s Range― - ―

52-Week Range¥44.00 - ¥120.00

Previous CloseN/A

Volume237.70K

Average Volume (3M)3.22M

Market Cap

¥20.34B

Enterprise Value¥22.38K

Total Cash (Recent Filing)¥835.88M

Total Debt (Recent Filing)¥688.34M

Price to Earnings (P/E)―

Beta0.76

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-14.10

Shares Outstanding398,835,540

10 Day Avg. Volume1,701,110

30 Day Avg. Volume3,216,076

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)7.04

Price to Sales (P/S)24.76

P/FCF Ratio-3.75

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth MomentumSustained revenue acceleration indicates improving product or partner traction for AnGes's pipeline. Over a 2-6 month horizon, stronger top-line momentum raises the odds of milestone-triggered licensing revenues and supports continued R&D investment without immediate reliance on dilutive capital.

Low Leverage / Financial FlexibilityA low-debt profile gives AnGes flexibility to fund clinical programs, negotiate partnerships, or raise capital on more favorable terms. For a biotech focused on development milestones, limited leverage reduces bankruptcy risk and preserves strategic optionality across 2-6 months and beyond.

Pipeline Monetization Business ModelA licensing and milestone-driven model fits biotech economics: successful trials or regulatory wins can generate outsized, non-linear cash inflows. This model aligns incentives with partners and, if clinical progress continues, can provide durable, high-value revenue events over the medium term.

Bears Say

Persistent Cash BurnChronic negative operating and free cash flow forces reliance on external financing or partner upfronts, increasing dilution or covenant risk. Continued cash burn constrains the pace of clinical development and heightens execution risk if material financing events do not occur within the next several quarters.

Ongoing Operating LossesWide and persistent operating losses mean the business is still far from break-even, limiting internal funding capacity for trials and commercialization. This ongoing unprofitability increases dependence on milestone events or partners and raises the bar for sustainable earnings quality over time.

Eroding Equity And AssetsA shrinking balance sheet reduces the firm’s financial cushion and its ability to absorb further losses or secure non-dilutive funding. Continued erosion of assets and equity weakens negotiating leverage with partners and heightens the risk that future setbacks would force more dilutive financing.

4563 FAQ

What was AnGes Inc’s price range in the past 12 months?

AnGes Inc lowest stock price was ¥44.00 and its highest was ¥120.00 in the past 12 months.

What is AnGes Inc’s market cap?

AnGes Inc’s market cap is ¥20.34B.

When is AnGes Inc’s upcoming earnings report date?

AnGes Inc’s upcoming earnings report date is Nov 06, 2026 which is in 84 days.

How were AnGes Inc’s earnings last quarter?

Currently, no data Available

Is AnGes Inc overvalued?

According to Wall Street analysts AnGes Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AnGes Inc pay dividends?

AnGes Inc does not currently pay dividends.

What is AnGes Inc’s EPS estimate?

AnGes Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AnGes Inc have?

AnGes Inc has 398,835,540 shares outstanding.

What happened to AnGes Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of AnGes Inc?

Currently, no hedge funds are holding shares in JP:4563

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AnGes Inc

AnGes, Inc. (4563) is a Japanese biotechnology company focused on developing and commercializing nucleic-acid–based medicines and gene therapies. The company’s activities center on research and development, clinical development, regulatory work, and potential out-licensing of drug candidates, with a portfolio historically associated with DNA plasmid–based therapeutics and other genetic medicine approaches. null